News
PRTC
27.48
+5.09%
1.33
Weekly Report: what happened at PRTC last week (0415-0419)?
Weekly Report · 3d ago
PureTech Health: Notice of Results
PureTech Health plc plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on April 25, 2024. The company is a clinical-stage biotherapeutics company. PureTech's R&D engine has resulted in the development of 28 therapeutic candidates.
Barchart · 04/18 01:00
PURETECH HEALTH: TOPLINE RESULTS ARE EXPECTED IN Q4 2024
Reuters · 04/16 11:00
Weekly Report: what happened at PRTC last week (0408-0412)?
Weekly Report · 04/15 11:13
- PURETECH HEALTH PLC - FDA GRANTS PRTC'S LYT-200 FAST TRACK DESIGNATION
Reuters · 04/11 11:00
PURETECH RECEIVES FDA FAST TRACK DESIGNATION FOR LYT-200 IN HEAD AND NECK CANCERS
Reuters · 04/11 11:00
PureTech Health Debuts Seaport Therapeutics and Reshuffles Leadership
TipRanks · 04/09 10:57
PureTech Launches Seaport Therapeutics With $100M Oversubscribed Series A; Daphne Zohar Steps Down To Lead Seaport; Bharatt Chowrira Appointed New CEO
Benzinga · 04/09 07:39
PureTech Names Bharatt Chowrira CEO As Daphne Zohar Turns CEO Of Newly Launched Seaport Therapeutics
NASDAQ · 04/09 06:48
PURETECH HEALTH - ERIC ELENKO PROMOTED TO PRESIDENT
Reuters · 04/09 06:03
PURETECH LAUNCHES SEAPORT THERAPEUTICS WITH $100 MILLION OVERSUBSCRIBED SERIES A AND ANNOUNCES MANAGEMENT TRANSITIONS
Reuters · 04/09 06:00
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
PureTech Health plc announces key progress on its strategic initiatives. Seaport Therapeutics has raised $100 million in an oversubscribed Series A financing to support the development of a novel clinical-stage pipeline of neuropsychiatric medicines. PureTech has named Bharatt Chowrira as Chief Executive Officer of the company. The company is the latest Founded Entity to be created by PureTech.
Barchart · 04/09 01:00
Weekly Report: what happened at PRTC last week (0401-0405)?
Weekly Report · 04/08 11:18
Weekly Report: what happened at PRTC last week (0325-0329)?
Weekly Report · 04/01 11:16
Weekly Report: what happened at PRTC last week (0318-0322)?
Weekly Report · 03/25 11:19
PureTech Health: Repeat What Works
PureTech Health's lead asset, LYT-100, may be a promising treatment for idiopathic pulmonary fibrosis. Karuna Therapeutics was acquired by BMY for $14 billion in December. The company has been successful in developing a therapeutic with an optimized profile.
Seeking Alpha · 03/23 11:52
Vor Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Vor Biopharma Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 39 cents per share. The mean expectation of analysts was for a loss of 50 cents. Vor Biopharm Inc shares had fallen by 20.0% this quarter.
Reuters · 03/21 12:01
Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)
TipRanks · 03/21 06:21
PureTech announces $100M capital return through tender offer
Healthcare PureTech announces $100M capital return through tender offer. The capital return represents approximately 14% of PureTech's market capitalization. The company will receive approximately $293M gross proceeds from its remaining stake in Karuna. PureTech Health plc (PRTC)
Seeking Alpha · 03/19 14:31
PureTech Health Announces $100 Million Shareholder Return
TipRanks · 03/19 13:27
More
Webull provides a variety of real-time PRTC stock news. You can receive the latest news about Puretech Health through multiple platforms. This information may help you make smarter investment decisions.
About PRTC
PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.